New combo therapy shows promise for tough transplant complication

This study tested adding a low dose of the drug Interleukin-2 (IL-2) to a standard therapy called extracorporeal photopheresis (ECP) for people with chronic graft-versus-host disease (GVHD) that did not respond to steroids. Chronic GVHD is a serious condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial enrolled 25 adults and measured how many had a response after 16 weeks of treatment. The goal was to see if the combination could better control the disease without causing severe side effects.